{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-116353","form_type":"8-K","ticker":"NKTX","cik":"0001787400","company_name":"Nkarta, Inc.","filed_at":"2022-04-25T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.319449+00:00","generated_at":"2026-06-26T05:06:45.199598+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Nkarta reports 60% CR for NKX101 in AML; 83% ORR for NKX019 in NHL","bullets":["NKX101: 3/5 AML patients at 1B/1.5B cells x3 achieved CR (60%); 2 of 3 CRs are MRD negative.","NKX019: 5/6 NHL patients at 1B cells x3 achieved response (83% ORR); 3/6 CR (50% CR).","No CRS, neurotoxicity, or GvHD reported for either program; safety profile favorable.","Both programs advancing to 1.5B cells x3 dose regimen for recommended Phase 2 dose.","Phase 1 trials continue enrolling; updated data to be submitted to future medical meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-116353","json":"https://secwatch.observer/filing/0001193125-22-116353.json","markdown":"https://secwatch.observer/filing/0001193125-22-116353.md","text":"https://secwatch.observer/filing/0001193125-22-116353.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787400/000119312522116353/0001193125-22-116353-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787400/000119312522116353/d219241d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T05:06:45.199598+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}